Phase II Open Label,Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody(CV-18C3)in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-popliteal Revascularization.

Trial Profile

Phase II Open Label,Randomized Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of an Anti-Inflammatory Therapeutic Antibody(CV-18C3)in Reducing Restenosis in Patients Undergoing Percutaneous Femoro-popliteal Revascularization.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs MABp1 (Primary)
  • Indications Vascular restenosis
  • Focus Adverse reactions
  • Sponsors XBiotech
  • Most Recent Events

    • 02 Oct 2015 Results published in the Journal of Vascular Surgery, according to a XBiotech media release.
    • 02 Oct 2015 Results published in a XBiotech media release.
    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top